Trials / Conditions / Hyperparathyroidism, Secondary

Hyperparathyroidism, Secondary

32 registered clinical trials studyying Hyperparathyroidism, Secondary.

Status	Trial	Sponsor	Phase
Withdrawn	Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease NCT03063190	University of Sao Paulo General Hospital	Phase 4
Completed	Frequency of Hyperparathyroidism in Postmenopausal Osteoporosis and Its Treatment NCT05347082	Hospital Regional 1o de Octubre	N/A
Unknown	Study on the Use of Cinacalcet in Phosphocalcic Context. NCT04126954	Hospices Civils de Lyon	—
Completed	Impact of Parathyroidectomy on Vascular Calcification and Clinical Outcome in Hemodialysis Patients NCT03724188	Mansoura General Hospital	—
Completed	Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass NCT02830789	University of Aarhus	N/A
Completed	Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy NCT05382988	Guangdong Provincial People's Hospital	Phase 3
Unknown	Optimal Anemia Treatment in End Stage Renal Disease (ERSD) NCT02273570	Azienda Ospedaliera Sant'Anna	N/A
Completed	Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoled NCT02274623	OPKO Health, Inc.	Phase 1
Completed	Analysis of Bone Microarchitecture With HR-pQCT of Patients With Chronic Kidney Disease (CKD) Candidates for R NCT02523209	Centre Hospitalier Universitaire de Saint Etienne	—
Completed	Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidne NCT02102204	Amgen	Phase 3
Completed	The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid NCT02056730	Chulalongkorn University	Phase 4
Completed	A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodial NCT01922843	Deltanoid Pharmaceuticals	Phase 2
Completed	Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SH NCT01932970	Amgen	Phase 3
Completed	Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chr NCT01785875	Amgen	Phase 3
Completed	Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002 NCT02282813	OPKO Health, Inc.	Phase 3
Completed	Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Pat NCT01785849	Amgen	Phase 3
Completed	Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Pat NCT01788046	Amgen	Phase 3
Completed	Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insuff NCT01704079	OPKO IP Holdings II, Inc.	Phase 3
Completed	Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insuff NCT01651000	OPKO IP Holdings II, Inc.	Phase 3
Unknown	Subtotal Parathyroidectomy or Total Parathyroidectomy With Autograft in Chronic Kidney Disease Patients Under NCT02464072	University of Sao Paulo General Hospital	N/A
Terminated	Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparat NCT01439867	Amgen	Phase 2
Terminated	Pediatric Chronic Kidney Disease Safety and Efficacy NCT01277510	Amgen	Phase 3
Completed	Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease NCT01290029	Amgen	Phase 1
Completed	Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Sub NCT01181531	Amgen	Phase 4
Completed	Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparath NCT01134562	KAI Pharmaceuticals	Phase 1
Completed	Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers NCT01134549	KAI Pharmaceuticals	Phase 1
Terminated	Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney Transplant Patients NCT00646282	Emory University	Phase 4
Completed	Mineral and Bone Disorders Outcomes in Stage 5D of Chronic Kidney Disease NCT00995163	Kyowa Kirin Co., Ltd.	—
Completed	How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis NCT00528788	Duke University	Phase 4
Completed	Oral Paricalcitol in Kidney Transplant Recipients NCT00587158	Mayo Clinic	N/A
Completed	Evaluation of Colecalciferol Substitution in Dialysis Patients NCT00397475	University Hospital, Saarland	N/A
Completed	CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis NCT00211939	Nabi Biopharmaceuticals	Phase 4